Background:
Tuberculosis (TB) has been a challenging disease worldwide, especially for the neglected poor populations. Presently, there are approximately 2 billion people infected with TB worldwide and 10 million people in the world fell ill with active TB, leading to 1.5 million deaths.
Introduction:
The classic treatment is extensive and the drug and multi drug resistance of Mycobacterium tuberculosis has been a threat to the efficacy of the drugs currently used. Therefore, the rational design of new anti TB candidates is urgently needed.
Methods:
With the aim of contributing to face this challenge, 78 compounds have been proposed based on SBDD (Structure Based Drug Design) strategies applied to target the M. tuberculosis phosphopantetheine adenylyltransferase (MtPPAT) enzyme. Ligand Based Drug Design (LBDD) strategies were also used for establishing structure activity relationships (SAR) and for optimizing the structures. MtPPAT is important for the biosynthesis of coenzyme A (CoA) and it has been studied recently toward the discovery of new inhibitors.
Results :
After docking simulations and enthalpy calculations, the interaction of selected compounds with MtPPAT was found to be energetically favorable. The most promising compounds were then synthesized and submitted to anti M. tuberculosis and MtPPAT inhibition assays.
Conclusion:
One of the compounds synthesized (MCP163), showed the highest activity in both of these assays.
Ligand- and Structure-Based Drug Design Strategies and PPARδ/α Selectivity
